31st Jul 2008 11:00
AstraZeneca Development Pipeline
31 July 2008
Line Extensions
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Cardiovascular |
|||||
|
Atacand |
angiotensin II antagonist |
diabetic retinopathy |
III |
1H 2009* |
1H 2009* |
|
Atacand Plus |
angiotensin II antagonist/thiazide diuretic |
32/12.5 mg, 32/25 mg for hypertension |
III |
Filed |
|
|
Crestor |
statin |
outcomes end stage renal disease |
III |
1H 2009 |
1H 2009 |
|
Crestor |
statin |
outcomes in subjects with elevated CRP |
III |
1H 2009 |
1H 2009 |
|
Onglyza (saxagliptin)/ metformin FDC |
DPP-4 inhibitor + biguanide FDC |
diabetes |
III |
2010 |
2010 |
|
Dapagliflozin/ metformin FDC |
SGLT2 inhibitor + biguanide FDC |
diabetes |
III |
2011 |
2011 |
|
Gastrointestinal |
|||||
|
Nexium Sachet formulation |
proton pump inhibitor |
GERD |
III |
Launched |
Launched |
|
Nexium |
proton pump inhibitor |
peptic ulcer bleeding |
III |
Filed |
Filed |
|
Nexium low dose aspirin combination |
proton pump inhibitor |
low dose aspirin associated peptic ulcer |
III |
1H 2009 |
|
|
Nexium |
proton pump inhibitor |
extra-oesophageal reflux disease |
II |
2H 2009* |
2H 2009* |
|
Neuroscience |
|||||
|
Seroquel XR |
D2/5HT2 antagonist |
schizophrenia |
III |
Launched |
Launched |
|
Seroquel |
D2/5HT2 antagonist |
bipolar maintenance |
III |
Filed |
Launched |
|
Seroquel |
D2/5HT2 antagonist |
bipolar depression |
III |
Filed |
Launched |
|
Seroquel XR |
D2/5HT2 antagonist |
major depressive disorder |
III |
Filed |
Filed |
|
Seroquel XR |
D2/5HT2 antagonist |
bipolar mania |
III |
Filed |
Filed |
|
Seroquel XR |
D2/5HT2 antagonist |
bipolar depression |
III |
Filed |
Filed |
|
Seroquel XR |
D2/5HT2 antagonist |
generalised anxiety disorder |
III |
4Q 2008 |
Filed |
|
Oncology & Infection |
|||||
|
FluMist |
live, attenuated, intranasal influenza virus vaccine |
influenza |
III |
4Q 2008 |
Launched |
|
Iressa |
EGFR tyrosine kinase inhibitor |
NSCLC |
III |
Filed |
|
|
Faslodex |
oestrogen receptor antagonist |
first line advanced breast cancer |
III |
||
|
Faslodex |
oestrogen receptor antagonist |
adjuvant |
III |
||
*Publication only.
Line Extensions (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Respiratory & Inflammation |
|||||
|
Symbicort pMDI |
inhaled steroid/fast onset, long-acting β2 agonist |
asthma |
III |
Filed* |
Launched** |
|
Symbicort pMDI |
inhaled steroid/fast onset, long-acting β2 agonist |
COPD |
III |
Filed* |
Filed |
\* To be supplemented in 2008 with data supporting two additional strengths.
**US approval based on 12 years and above.
NCEs
Phase III/Registration
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Cardiovascular |
|||||
|
Onglyza (saxagliptin) |
DPP-4 inhibitor |
diabetes |
III |
Filed |
Filed |
|
AZD6140 |
ADP receptor antagonist |
arterial thrombosis |
III |
2H 2009 |
2H 2009 |
|
Crestor/TriLipix |
statin + fibrate fixed combination |
dyslipidaemia |
III |
2H 2009 |
|
|
Dapagliflozin |
SGLT2 inhibitor |
diabetes |
III |
2010 |
2010 |
|
AZD0837 |
thrombin inhibitor |
thrombosis |
III |
2012 |
2012 |
|
Neuroscience |
|||||
|
PN400 |
naproxen +esomeprazole |
signs and symptoms of OA , RA, and AS |
III |
2H 2009 |
1H 2009 |
|
Oncology & Infection |
|||||
|
Motavizumab |
humanized MAb binding to RSV F protein |
RSV prevention |
III |
1H 2009 |
Filed |
|
Zactima |
VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity |
NSCLC |
III |
1H 2009 |
1H 2009 |
|
Recentin |
VEGFR tyrosine kinase inhibitor |
CRC |
III |
2010 |
2010 |
|
Recentin |
VEGFR tyrosine kinase inhibitor |
recurrent glioblastoma |
III |
2010 |
2010 |
|
MEDI-561 (IPI-504) |
Hsp90 inhibitor |
GIST |
III |
2010 |
2010 |
|
ZD4054 |
endothelin A receptor antagonist |
hormone resistant prostate cancer |
III |
2011 |
2011 |
NCEs
Phases I and II
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Cardiovascular |
|||||
|
AZD2207 |
CB1 antagonist |
diabetes/obesity |
II |
||
|
AZD1305 |
antiarrhythmic |
arrhythmias |
II |
||
|
AZD6370 |
GK activator |
diabetes |
II |
||
|
AZD1175 |
CB1 antagonist |
diabetes/obesity |
I |
||
|
AZD6482 |
PI3K-beta inhibitor |
thrombosis |
I |
||
|
AZD1656 |
GK activator |
diabetes/obesity |
I |
||
|
Gastrointestinal |
|||||
|
AZD3355 |
inhibitor of transient lower oesophageal sphincter relaxations (TLESR) |
GERD |
II |
2011 |
2011 |
|
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
GERD |
I |
||
|
AZD1386 |
vanilloid receptor 1 antagonist |
GERD |
I |
||
|
Neuroscience |
|||||
|
AZD3480 |
neuronal nicotinic receptor agonist |
cognitive disorders in schizophrenia |
II |
2011 |
2011 |
|
AZD3480 |
neuronal nicotinic receptor agonist |
Alzheimer's disease |
II |
2011 |
2011 |
|
AZD6765 |
NMDA receptor antagonist |
depression |
II |
2012 |
2012 |
|
AZD1940 |
CB1 receptor agonist |
nociceptive and neuropathic pain |
II |
||
|
AZD0328 |
selective neuronal nicotinic receptor agonist |
Alzheimer's disease |
II |
||
|
AZD1386 |
vanilloid receptor antagonist |
chronic nociceptive pain |
II |
||
|
AZD2624 |
NK receptor antagonist |
schizophrenia |
II |
||
|
AZD2327 |
enkephalinergic receptor modulator |
anxiety and depression |
I |
||
|
AZD5904 |
myeloperoxidase (MPO) inhibitor |
multiple sclerosis |
I |
||
|
AZD3241 |
inhibitor of myeloperoxidase (MPO) |
Parkinson's disease |
I |
||
|
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
chronic nociceptive pain |
I |
||
|
AZD7325 |
GABA receptor subtype partial agonist |
anxiety |
I |
||
|
AZD6280 |
GABA receptor subtype partial agonist |
anxiety |
I |
||
|
TC-5619 |
neuronal nicotinic receptor agonist |
cognitive disorders in schizophrenia |
I |
||
|
AZD1704 |
CB1 receptor agonist |
analgesia |
I |
||
NCEs
Phases I and II (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Oncology & Infection |
|||||
|
Motavizumab |
humanized MAb binding to RSV F protein |
early and late treatment of RSV in paeds >1 yr |
II |
||
|
Zactima |
VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity |
medullary thyroid cancer |
II |
1H 2009 |
1H 2009 |
|
Recentin |
VEGFR tyrosine kinase inhibitor |
NSCLC |
II |
||
|
CytoFab |
anti-TNF-alpha polyclonal antibody |
severe sepsis |
II |
||
|
AZD6244 (ARRY-142886) |
MEK inhibitor |
solid tumours |
II |
2014 |
2014 |
|
AZD2281 |
PARP inhibitor |
breast cancer/ovarian |
II |
2012 |
2012 |
|
EBV vaccine* |
Epstein-Barr virus vaccine |
post-transplant proliferative disease |
II |
||
|
AZD2836 |
NS 5a inhibitor |
hepatitis C |
II |
||
|
AZD0530 |
SRC kinase inhibitor |
solid tumours and haematological malignancies |
II |
||
|
MEDI-561 (IPI-504) |
Hsp90 inhibitor |
range of solid tumours |
II |
||
|
MEDI-538* |
CD19 B cells |
leukaemia/lymphoma |
II |
||
|
AZD4877 |
cell cycle agent |
solid tumours and haematological malignancies |
II |
||
|
AZD1152 |
aurora kinase inhibitor |
solid tumours and haematological malignancies |
I |
||
|
AZD4769 |
EGFR tyrosine kinase inhibitor |
solid tumours |
I |
||
|
AZD8931 |
erbB kinase inhibitor |
solid tumours |
I |
||
|
AZD7762 |
CHK1 kinase Inhibitor |
solid tumours |
I |
||
|
AZD8330 (ARRY-424704) |
MEK inhibitor |
solid tumours |
I |
||
|
CAT-8015 |
recombinant immunotoxin |
haematological malignancies |
I |
||
|
MEDI-534 |
RSV/PIV-3 vaccine |
intranasal immunisation |
I |
||
|
MEDI-560 |
PIV-3 vaccine |
intranasal immunisation |
I |
||
|
MEDI-566 |
pandemic influenza virus vaccine |
pandemic influenza vaccine |
I |
||
|
MEDI-564* |
RSV F protein inhibitor |
RSV treatment |
I |
||
|
CMV Vaccine |
CMV vaccine |
cytomegalovirus |
I |
||
|
MEDI-557 |
YTE - extended half-life RSV MAb |
RSV prophylaxis |
I |
||
|
AZD7295 |
NS 5a inhibitor |
hepatitis C |
I |
||
|
IPI-493 |
oral HSP 90 inhibitor |
solid tumours |
I |
||
|
AZD8055 |
TOR kinase inhibitor |
range of tumours |
I |
||
*Partnered product
NCEs
Phases I and II (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Respiratory & Inflammation |
|||||
|
AZD9056 |
ion channel blocker (P2X7) |
rheumatoid arthritis |
II |
2012 |
2012 |
|
AZD5672 |
chemokine receptor antagonist (CCR5) |
rheumatoid arthritis |
II |
2012 |
2012 |
|
AZD1981 |
CRTh2 receptor antagonist |
asthma/COPD |
II |
||
|
MEDI-528 |
anti-IL-9 antibody |
asthma |
II |
||
|
CAT-354 |
anti-IL-13 antibody |
asthma |
II |
||
|
AZD4818 |
CCR1 receptor antagonist |
COPD |
II |
||
|
AZD9668 |
neutrophil elastase inhibitor |
COPD |
II |
||
|
AZD1236 |
matrix metallo-proteinase inhibitor |
COPD |
I |
||
|
MEDI-563 |
anti-IL-5R antibody |
asthma |
I |
||
|
MEDI-545 |
anti-IFN-alpha antibody |
SLE, myositis |
I |
||
|
Pneumococcal vaccine* |
pneumococcal vaccine |
streptococcus pneumoniae |
I |
||
|
AZD3199 |
iLABA |
asthma/COPD |
I |
||
|
CAM-3001 |
anti-GM-CSFR |
rheumatoid arthritis |
I |
||
|
AZD8848 |
asthma |
I |
|||
*Partnered product
AstraZeneca Development Pipeline
Discontinued Projects vs 31 January 2008 FY
Cardiovascular & Gastrointestinal
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD4121 |
dyslipidaemia |
Respiratory & Inflammation
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD1744 |
COPD |
|
NCE |
AZD5904 |
COPD |
Comments
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Compounds in development are displayed by phase.
Abbreviations:
MAA - Marketing Authorisation Application (Europe).
NDA - New Drug Application/Biologics Licensing Application (USA).
Related Shares:
Astrazeneca